Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now? [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. Astellas Pharma (ALPMY) is a stock many investors are watching right now. ALPMY is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Investors should also note that ALPMY holds a PEG ratio of 1.15. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ALPMY's industry currently sports an average PEG of 2.2
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management [Yahoo! Finance]Yahoo! Finance
- Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementPR Newswire
- KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates [Yahoo! Finance]Yahoo! Finance
- Should Value Investors Buy Astellas Pharma (ALPMY) Stock? [Yahoo! Finance]Yahoo! Finance